Skip to main
OBIO

OBIO Stock Forecast & Price Target

OBIO Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Orchestra BioMed Holdings Inc. showcases a promising outlook supported by a significant protocol update that enhances the potential patient pool for its product candidates by over 24-fold, with an enrollment target of 500 patients by mid-2026. The company's investment in research and development, reflected by a 21% increase in R&D expenses to $14.0 million, underscores its commitment to advancing innovative therapies, particularly in addressing isolated systolic hypertension and related conditions. Furthermore, the strategic collaborations with established medical device companies aim to leverage market penetration and drive sales growth for its flagship products, which could further enhance the company's market position and financial performance.

Bears say

Orchestra BioMed Holdings Inc. faces a challenging financial outlook due to its ongoing operating losses since inception, which raise concerns about the company's ability to achieve and sustain profitability. Furthermore, the extended timelines and potential escalating costs associated with clinical trials for its flagship product candidates may hinder their development and success in proving safety and effectiveness. Additionally, there are risks regarding the adequacy of key intellectual property protections, which could adversely affect the commercialization of its products.

OBIO has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Orchestra BioMed Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Orchestra BioMed Holdings Inc (OBIO) Forecast

Analysts have given OBIO a Strong Buy based on their latest research and market trends.

According to 5 analysts, OBIO has a Strong Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Orchestra BioMed Holdings Inc (OBIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.